NFkB p65 Antibody (Clone 2A12A7)
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IP |
---|---|
Primary Accession | Q04207 |
Other Accession | NP_033071 |
Reactivity | Human, Mouse, Rat |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse IgG1 |
Clone Names | 2A12A7 |
Calculated MW | 60212 Da |
Gene ID | 19697 |
---|---|
Application & Usage | Western blot analysis (1-4 µg/ml). However, the optimal conditions should be determined individually. A431 cells can be used as a positive control. |
Other Names | RELA, NFKB3, MGC131774 |
Target/Specificity | NFkB p65 |
Antibody Form | Liquid |
Appearance | Colorless liquid |
Formulation | 100 µg (200 µg/ml) in PBS containing 1 mg/ml BSA and 1.5 mM sodium azide and 50% glycerol. |
Handling | The antibody solution should be gently mixed before use. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | NFkB p65 Antibody (Clone 2A12A7) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Rela |
---|---|
Synonyms | Nfkb3 |
Function | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain- containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I- kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I- kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA- binding site which could contribute directly to DNA binding in the NF- kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression (PubMed:29813070). Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (By similarity). The NF-kappa-B homodimeric RELA- RELA complex appears to be involved in invasin-mediated activation of IL-8 expression (By similarity). |
Cellular Location | Nucleus. Cytoplasm Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B) (PubMed:21131967). Colocalized with DDX1 in the nucleus upon TNF-alpha induction (By similarity) Colocalizes with GFI1 in the nucleus after lipopolysaccharide (LPS) stimulation. {ECO:0000250|UniProtKB:Q04206, ECO:0000269|PubMed:21131967} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NFkB was identified as a sequence specific transcriptional activator that binds to the intronic enhancer of kappa light chain gene in B lymphocytes. NFkB is a heterodimer that consists of a 50 kDa DNA binding subunit (p50) and a 65 kDa transactivation subunit (p65/RelA). Both of these subunits exhibit sequence homology to the protooncogene c-Rel. The p50/p65 heterodimer remains in the cytosol in an inactive form as a complex with its inhibitor, IkB. Upon stimulation of cells by a wide variety of stimuli such as lipopolysaccharide (LPS), pro-inflammatory cytokines, and viral infection. IkB is phosphorylated and degraded by proteosome. The active NFkB heterodimer is translocated into the nucleus and induces gene expression.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.